These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 37791732)

  • 21. Who can safely evade a magnetic resonance imaging fusion-targeted biopsy (MRIFTB) for prostate imaging reporting and data system (PI-RADS) 3 lesion?
    Kim M; Ryu H; Lee HJ; Hwang SI; Choe G; Hong SK
    World J Urol; 2021 May; 39(5):1463-1471. PubMed ID: 32696126
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of prostate cancer detection in MRI PI-RADS 3 lesions - Reality of a tertiary center.
    Araújo D; Gromicho A; Dias J; Bastos S; Maciel RM; Sabença A; Xambre L
    Arch Ital Urol Androl; 2023 Dec; 95(4):11830. PubMed ID: 38117217
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A practical primer on PI-RADS version 2: a pictorial essay.
    Horn GL; Hahn PF; Tabatabaei S; Harisinghani M
    Abdom Radiol (NY); 2016 May; 41(5):899-906. PubMed ID: 26984751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of multiplicity of PI-RADS 3 lesions on cancer detection rate of confirmatory targeted biopsy in patients diagnosed with prostate cancer and managed with active surveillance.
    Yaguchi G; Tang HJ; Deebajah M; Keeley J; Pantelic M; Williamson S; Gupta N; Peabody JO; Menon M; Dabaja A; Alanee S
    Urol Oncol; 2020 Jun; 38(6):599.e9-599.e13. PubMed ID: 32265090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Performance of PI-RADS v2 assessment categories assigned prior to MR-US fusion biopsy in a new fusion biopsy program.
    Trent GP; Ye N; Chopra J; Chen R; Wong-You-Cheong J; Naslund M; Siddiqui MM; Wnorowski A
    Clin Imaging; 2020 Aug; 64():29-34. PubMed ID: 32220760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MRI in-bore biopsy following MRI/US fusion-guided biopsy in patients with persistent suspicion of clinically significant prostate cancer.
    Quentin M; Boschheidgen M; Radtke JP; Spohn F; Ullrich T; Drewes L; Valentin B; Lakes J; Al-Monajjed ; Arsov C; Esposito I; Albers P; Antoch G; Schimmöller L
    Eur J Radiol; 2024 Jun; 175():111436. PubMed ID: 38522396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of PI-RADS version 2 and PI-RADS version 2.1 for the detection of transition zone prostate cancer.
    Tamada T; Kido A; Takeuchi M; Yamamoto A; Miyaji Y; Kanomata N; Sone T
    Eur J Radiol; 2019 Dec; 121():108704. PubMed ID: 31669798
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness and Accuracy of MRI-Ultrasound Fusion Targeted Biopsy Based on PI-RADS v2.1 Category in Transition/Peripheral Zone of the Prostate.
    Liu Y; Wang S; Xu G; Zhou B; Zhang Y; Ye B; Xiang L; Zhang Y; Xu H
    J Magn Reson Imaging; 2023 Sep; 58(3):709-717. PubMed ID: 36773016
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the ESUR PI-RADS scoring system for multiparametric MRI of the prostate with targeted MR/TRUS fusion-guided biopsy at 3.0 Tesla.
    Roethke MC; Kuru TH; Schultze S; Tichy D; Kopp-Schneider A; Fenchel M; Schlemmer HP; Hadaschik BA
    Eur Radiol; 2014 Feb; 24(2):344-52. PubMed ID: 24196383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utility of positive core number on MRI-ultrasound fusion targeted biopsy in combination with PI-RADS scores for predicting unexpected extracapsular extension of clinically localized prostate cancer.
    Kobayashi M; Matsuoka Y; Uehara S; Tanaka H; Fujiwara M; Nakamura Y; Ishikawa Y; Fukuda S; Waseda Y; Tanaka H; Yoshida S; Fujii Y
    Int J Urol; 2024 Jul; 31(7):739-746. PubMed ID: 38468553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Accuracy of MRI-ultrasound fusion-guided and systematic biopsy of the prostate.
    In de Braekt T; van Rooij SBT; Daniels-Gooszen AW; Scheepens WA; de Jongh R; Bosch SL; Nederend J
    Br J Radiol; 2024 May; 97(1158):1132-1138. PubMed ID: 38627253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Followup of Men with PI-RADS™ 4 or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy.
    Meng X; Chao B; Chen F; Huang R; Taneja SS; Deng FM
    J Urol; 2021 Mar; 205(3):748-754. PubMed ID: 33080145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate.
    Boschheidgen M; Schimmöller L; Doerfler S; Al-Monajjed R; Morawitz J; Ziayee F; Mally D; Quentin M; Arsov C; Albers P; Antoch G; Ullrich T
    Sci Rep; 2022 Apr; 12(1):6746. PubMed ID: 35469056
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Retrospective comparison of direct in-bore magnetic resonance imaging (MRI)-guided biopsy and fusion-guided biopsy in patients with MRI lesions which are likely or highly likely to be clinically significant prostate cancer.
    Venderink W; van der Leest M; van Luijtelaar A; van de Ven WJM; Fütterer JJ; Sedelaar JPM; Huisman HJ
    World J Urol; 2017 Dec; 35(12):1849-1855. PubMed ID: 28871396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can high b-value 3.0 T biparametric MRI with the Simplified Prostate Image Reporting and Data System (S-PI-RADS) be used in biopsy-naïve men?
    Wang G; Yu G; Chen J; Yang G; Xu H; Chen Z; Wang G; Bai Z
    Clin Imaging; 2022 Aug; 88():80-86. PubMed ID: 34243992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective Evaluation of PI-RADS Version 2.1 for Prostate Cancer Detection and Investigation of Multiparametric MRI-derived Markers.
    Yilmaz EC; Shih JH; Belue MJ; Harmon SA; Phelps TE; Garcia C; Hazen LA; Toubaji A; Merino MJ; Gurram S; Choyke PL; Wood BJ; Pinto PA; Turkbey B
    Radiology; 2023 May; 307(4):e221309. PubMed ID: 37129493
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Using Prostate Imaging-Reporting and Data System (PI-RADS) Scores to Select an Optimal Prostate Biopsy Method: A Secondary Analysis of the Trio Study.
    Ahdoot M; Lebastchi AH; Long L; Wilbur AR; Gomella PT; Mehralivand S; Daneshvar MA; Yerram NK; O'Connor LP; Wang AZ; Gurram S; Bloom J; Siddiqui MM; Linehan WM; Merino M; Choyke PL; Pinsky P; Parnes H; Shih JH; Turkbey B; Wood BJ; Pinto PA;
    Eur Urol Oncol; 2022 Apr; 5(2):176-186. PubMed ID: 33846112
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Avoiding Unnecessary Systematic Biopsy in Clinically Significant Prostate Cancer: Comparison Between MRI-Based Radiomics Model and PI-RADS Category.
    Cheng X; Chen Y; Xu H; Ye L; Tong S; Li H; Zhang T; Tian S; Qi J; Zeng H; Yao J; Song B
    J Magn Reson Imaging; 2023 Feb; 57(2):578-586. PubMed ID: 35852438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative Analysis of Diffusion Weighted Imaging May Improve Risk Stratification of Prostatic Transition Zone Lesions.
    Engel H; Oerther B; Reisert M; Kellner E; Sigle A; Gratzke C; Bronsert P; Krauss T; Bamberg F; Benndorf M
    In Vivo; 2022; 36(5):2323-2331. PubMed ID: 36099133
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In-bore MR prostate biopsy - initial experience.
    Rembak-Szynkiewicz J; Wojcieszek P; Hebda A; Mazgaj P; Badziński A; Stasik-Pres G; Chmielik E; Bobek-Billewicz B
    Endokrynol Pol; 2022; 73(4):712-724. PubMed ID: 35971938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.